Maternal Supplemental PUFA Intake
BehavioralMaternal Supplemental PUFA Intake included sources from the questionnaires and plasma
NCT Number: NCT03468959
This study is to examine the association between maternal omega3 and other polyunsaturated fatty acids (PUFAs) during pregnancy and autism spectrum disorder (ASD) as well as other non-typical development (Non-TD) in the prospective Markers of Autism Risk in Babies-Learning Early Signs (MARBLES) cohort.
Looking for future studies?
Notify Me3 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
Time frame: 36 months
number of people with ASD
Time frame: 36 months
number of typically developed people
Time frame: 36 months
number of people with non-typical development
University of California, Davis
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06352372
Autism Spectrum Disorder, Autistic Disorder
Phoenix, Arizona, United States
View Trial DetailsNCT07277101
Autism Spectrum Disorder, Autistic Disorder
Shanghai, China
View Trial DetailsNCT06361147
Autism Spectrum Disorder, Child Development Disorders, Pervasive
Heraklion, Crete, Greece
View Trial DetailsNCT06508515
Autism Spectrum Disorder, Child Development Disorders, Pervasive
Seattle, Washington, United States
View Trial Details